Trevi Therapeutics Stock Cash Per Share

TRVI Stock

USD 4.36 0.24 5.83%

Trevi Therapeutics fundamentals help investors to digest information that contributes to Trevi Therapeutics' financial success or failures. It also enables traders to predict the movement of Trevi Stock. The fundamental analysis module provides a way to measure Trevi Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Trevi Therapeutics stock.

		Last Reported	Projected for Next Year
	Cash Per Share	0.96	0.92

The current Cash Per Share is estimated to decrease to 0.92.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Trevi Therapeutics Company Cash Per Share Analysis

Trevi Therapeutics' Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.

Cash Per Share

Total Cash

Average Shares

More About Cash Per Share | All Equity Analysis

Current Trevi Therapeutics Cash Per Share

1.82 X

Most of Trevi Therapeutics' fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Trevi Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Trevi Cash Per Share Driver Correlations

Understanding the fundamental principles of building solid financial models for Trevi Therapeutics is extremely important. It helps to project a fair market value of Trevi Stock properly, considering its historical fundamentals such as Cash Per Share. Since Trevi Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Trevi Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Trevi Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Long Term Debt Total	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Net Debt	Net Invested Capital	Net Working Capital	Capital Stock	Capital Surpluse	Current Deferred Revenue
Total Assets		0.94	0.9	-0.88	0.83	-0.09	0.68	-0.09	-0.6	-0.15	1.0	-0.63	0.66	0.62	-0.3	0.91	0.99	-0.6	0.83	-0.32
Total Stockholder Equity	0.94		0.93	-0.92	0.78	-0.16	0.72	-0.15	-0.72	-0.34	0.94	-0.75	0.69	0.65	-0.42	0.95	0.92	-0.63	0.76	-0.57
Net Tangible Assets	0.9	0.93		-0.92	0.84	0.06	0.72	0.02	-0.5	-0.08	0.9	-0.65	0.5	0.68	-0.52	0.91	0.9	-0.75	0.79	-0.57
Retained Earnings	-0.88	-0.92	-0.92		-0.86	0.14	-0.62	0.24	0.58	0.29	-0.88	0.71	-0.7	-0.59	0.35	-0.93	-0.85	0.66	-0.88	0.54
Accounts Payable	0.83	0.78	0.84	-0.86		0.21	0.71	0.01	-0.39	-0.19	0.83	-0.58	0.5	0.7	-0.29	0.87	0.77	-0.83	0.81	-0.26
Long Term Debt	-0.09	-0.16	0.06	0.14	0.21		0.44	0.91	0.22	0.17	-0.08	-0.1	-0.37	0.56	-0.5	0.04	-0.1	-0.6	-0.24	0.25
Net Receivables	0.68	0.72	0.72	-0.62	0.71	0.44		0.39	-0.7	-0.42	0.68	-0.82	0.48	0.97	-0.78	0.81	0.63	-0.87	0.43	-0.24
Long Term Debt Total	-0.09	-0.15	0.02	0.24	0.01	0.91	0.39		0.16	0.2	-0.09	-0.11	-0.4	0.51	-0.52	-0.03	-0.08	-0.45	-0.42	0.23
Total Liab	-0.6	-0.72	-0.5	0.58	-0.39	0.22	-0.7	0.16		0.72	-0.59	0.88	-0.74	-0.61	0.52	-0.68	-0.54	0.39	-0.39	0.33
Short Long Term Debt	-0.15	-0.34	-0.08	0.29	-0.19	0.17	-0.42	0.2	0.72		-0.15	0.71	-0.68	-0.43	0.22	-0.43	-0.07	0.24	-0.06	0.27
Total Current Assets	1.0	0.94	0.9	-0.88	0.83	-0.08	0.68	-0.09	-0.59	-0.15		-0.62	0.65	0.62	-0.3	0.9	0.99	-0.6	0.83	-0.32
Short Term Debt	-0.63	-0.75	-0.65	0.71	-0.58	-0.1	-0.82	-0.11	0.88	0.71	-0.62		-0.71	-0.83	0.68	-0.81	-0.56	0.69	-0.43	0.42
Common Stock	0.66	0.69	0.5	-0.7	0.5	-0.37	0.48	-0.4	-0.74	-0.68	0.65	-0.71		0.43	-0.15	0.75	0.62	-0.25	0.63	-0.3
Property Plant Equipment	0.62	0.65	0.68	-0.59	0.7	0.56	0.97	0.51	-0.61	-0.43	0.62	-0.83	0.43		-0.76	0.79	0.57	-0.92	0.33	-0.23
Net Debt	-0.3	-0.42	-0.52	0.35	-0.29	-0.5	-0.78	-0.52	0.52	0.22	-0.3	0.68	-0.15	-0.76		-0.47	-0.29	0.68	-0.13	0.4
Net Invested Capital	0.91	0.95	0.91	-0.93	0.87	0.04	0.81	-0.03	-0.68	-0.43	0.9	-0.81	0.75	0.79	-0.47		0.87	-0.76	0.75	-0.48
Net Working Capital	0.99	0.92	0.9	-0.85	0.77	-0.1	0.63	-0.08	-0.54	-0.07	0.99	-0.56	0.62	0.57	-0.29	0.87		-0.54	0.8	-0.34
Capital Stock	-0.6	-0.63	-0.75	0.66	-0.83	-0.6	-0.87	-0.45	0.39	0.24	-0.6	0.69	-0.25	-0.92	0.68	-0.76	-0.54		-0.45	0.32
Capital Surpluse	0.83	0.76	0.79	-0.88	0.81	-0.24	0.43	-0.42	-0.39	-0.06	0.83	-0.43	0.63	0.33	-0.13	0.75	0.8	-0.45		-0.35
Current Deferred Revenue	-0.32	-0.57	-0.57	0.54	-0.26	0.25	-0.24	0.23	0.33	0.27	-0.32	0.42	-0.3	-0.23	0.4	-0.48	-0.34	0.32	-0.35

Click cells to compare fundamentals

Trevi Cash Per Share Historical Pattern

Today, most investors in Trevi Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Trevi Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's cash per share growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Trevi Therapeutics cash per share as a starting point in their analysis.

Trevi Therapeutics Cash Per Share

Timeline

Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.

Competition

Predict Trevi Therapeutics

Cash Per Share Over Time

Trevi Common Stock Shares Outstanding

Common Stock Shares Outstanding

119.58 Million

As of now, Trevi Therapeutics' Common Stock Shares Outstanding is increasing as compared to previous years.

In accordance with the recently published financial statements, Trevi Therapeutics has a Cash Per Share of 1.82 times. This is 58.16% lower than that of the Pharmaceuticals sector and 57.97% lower than that of the Health Care industry. The cash per share for all United States stocks is 63.67% higher than that of the company.

Trevi Cash Per Share Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Trevi Therapeutics' direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Trevi Therapeutics could also be used in its relative valuation, which is a method of valuing Trevi Therapeutics by comparing valuation metrics of similar companies.

Trevi Therapeutics is currently under evaluation in cash per share category among its peers.

Trevi Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of Trevi Therapeutics from analyzing Trevi Therapeutics' financial statements. These drivers represent accounts that assess Trevi Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Trevi Therapeutics' important valuation drivers and their relationship over time.

	2020	2021	2022	2023	2024	2025 (projected)
Market Cap	43.7M	17.9M	124.6M	132.7M	119.4M	63.2M
Enterprise Value	12.9M	(4.3M)	121.2M	101.6M	116.9M	64.4M

Trevi Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Trevi Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Trevi Therapeutics' managers, analysts, and investors.

Environmental

Governance

Social

Trevi Fundamentals

	Return On Equity	-0.6
	Return On Asset	-0.37
	Current Valuation	303.81 M
	Shares Outstanding	89.37 M
	Shares Owned By Insiders	1.00 %
	Shares Owned By Institutions	70.42 %
	Number Of Shares Shorted	4.66 M
	Price To Book	6.24 X
	EBITDA	(33.8 M)
	Net Income	(29.07 M)
	Cash And Equivalents	77.86 M
	Cash Per Share	1.82 X
	Total Debt	1.34 M
	Debt To Equity	0.21 %
	Current Ratio	5.18 X
	Book Value Per Share	0.78 X
	Cash Flow From Operations	(31.71 M)
	Short Ratio	1.30 X
	Earnings Per Share	(0.44) X
	Target Price	9.81
	Number Of Employees	27
	Beta	1.01
	Market Capitalization	368.19 M
	Total Asset	89.4 M
	Retained Earnings	(239.13 M)
	Working Capital	81.72 M
	Net Asset	89.4 M

About Trevi Therapeutics Fundamental Analysis

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC